117 related articles for article (PubMed ID: 37566798)
41. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
[TBL] [Abstract][Full Text] [Related]
42. Automated SPE-based synthesis of 16α-[
Fedorova O; Nikolaeva V; Krasikova R
Appl Radiat Isot; 2018 Nov; 141():57-63. PubMed ID: 30176563
[TBL] [Abstract][Full Text] [Related]
43. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
[TBL] [Abstract][Full Text] [Related]
44. Differences in lung injury after IMRT or proton therapy assessed by
Shusharina N; Liao Z; Mohan R; Liu A; Niemierko A; Choi N; Bortfeld T
Radiother Oncol; 2018 Jul; 128(1):147-153. PubMed ID: 29352608
[TBL] [Abstract][Full Text] [Related]
45. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
46. A Randomized Feasibility Study of
Chae SY; Kim SB; Ahn SH; Kim HO; Yoon DH; Ahn JH; Jung KH; Han S; Oh SJ; Lee SJ; Kim HJ; Son BH; Gong G; Lee HS; Moon DH
J Nucl Med; 2017 Apr; 58(4):563-568. PubMed ID: 27688475
[TBL] [Abstract][Full Text] [Related]
47. Optimization of the alkyl side chain length of fluorine-18-labeled 7α-alkyl-fluoroestradiol.
Okamoto M; Shibayama H; Naka K; Kitagawa Y; Ishiwata K; Shimizu I; Toyohara J
Nucl Med Biol; 2016 Aug; 43(8):512-9. PubMed ID: 27289329
[TBL] [Abstract][Full Text] [Related]
48. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
49. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
Mortimer JE; Dehdashti F; Siegel BA; Trinkaus K; Katzenellenbogen JA; Welch MJ
J Clin Oncol; 2001 Jun; 19(11):2797-803. PubMed ID: 11387350
[TBL] [Abstract][Full Text] [Related]
50. Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer.
Castillo R; Pham N; Ansari S; Meshkov D; Castillo S; Li M; Olanrewaju A; Hobbs B; Castillo E; Guerrero T
Radiat Oncol; 2014 Mar; 9():74. PubMed ID: 24625207
[TBL] [Abstract][Full Text] [Related]
51. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
[TBL] [Abstract][Full Text] [Related]
52. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
53. Correlation of Functional Lung Heterogeneity and Dosimetry to Radiation Pneumonitis using Perfusion SPECT/CT and FDG PET/CT Imaging.
Lee HJ; Zeng J; Vesselle HJ; Patel SA; Rengan R; Bowen SR
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1255-1264. PubMed ID: 30108002
[TBL] [Abstract][Full Text] [Related]
54. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
[TBL] [Abstract][Full Text] [Related]
55. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
Liao GJ; Clark AS; Schubert EK; Mankoff DA
J Nucl Med; 2016 Aug; 57(8):1269-75. PubMed ID: 27307345
[TBL] [Abstract][Full Text] [Related]
56. [18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice.
Bénard F; Ahmed N; Beauregard JM; Rousseau J; Aliaga A; Dubuc C; Croteau E; van Lier JE
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1473-9. PubMed ID: 18360749
[TBL] [Abstract][Full Text] [Related]
57. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
[TBL] [Abstract][Full Text] [Related]
58. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes.
Jonson SD; Bonasera TA; Dehdashti F; Cristel ME; Katzenellenbogen JA; Welch MJ
Nucl Med Biol; 1999 Jan; 26(1):123-30. PubMed ID: 10096512
[TBL] [Abstract][Full Text] [Related]
59. In vivo imaging of brain estrogen receptors in rats: a 16α-18F-fluoro-17β-estradiol PET study.
Khayum MA; de Vries EF; Glaudemans AW; Dierckx RA; Doorduin J
J Nucl Med; 2014 Mar; 55(3):481-7. PubMed ID: 24481026
[TBL] [Abstract][Full Text] [Related]
60. Can
Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A
World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
